{"id":1002560,"date":"2026-09-10T10:26:03","date_gmt":"2026-09-10T14:26:03","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/suewallst-reminds-ars-pharmaceuticals-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-october-5-2026-spry\/"},"modified":"2026-09-10T10:26:03","modified_gmt":"2026-09-10T14:26:03","slug":"suewallst-reminds-ars-pharmaceuticals-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-october-5-2026-spry","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/suewallst-reminds-ars-pharmaceuticals-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-october-5-2026-spry\/","title":{"rendered":"SueWallSt Reminds ARS Pharmaceuticals Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of October 5, 2026 – SPRY"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n Eric Karas, ARS Pharmaceuticals’ Chief Commercial Officer, is named as a defendant in a securities class action alleging investors were misled about the timing of expanded CVS Caremark coverage for neffy before SPRY shares fell 23.9% in one session.<\/i>\n <\/p>\n

\n NEW YORK<\/span>, Sept. 10, 2026<\/span> \/PRNewswire\/ — SueWallSt notifies investors that Eric Karas, Chief Commercial Officer of ARS Pharmaceuticals Inc. (NASDAQ: SPRY), is named as an individual defendant in a securities class action brought on behalf of purchasers of SPRY securities between March 9, 2026 and June 24, 2026. Find out if you could qualify to recover your per-share losses<\/a>. You may also contact Joseph E. Levi, Esq. at jlevi@SueWallSt.com<\/a>\u00a0or (888) SueWallSt.<\/p>\n

\n

\n \"SueWallSt.com\"\n <\/p>\n<\/p><\/div>\n

SPRY shares closed at $10.54 on June 24, 2026 and fell to $8.02 the following session, a decline of $2.52 per share, or 23.9%, across roughly 99.3 million shares outstanding. LEAD PLAINTIFF DEADLINE: October 5, 2026.<\/p>\n

\n Karas’s Role During the Class Period<\/b>\n <\/p>\n

As Chief Commercial Officer, Karas held responsibility for market access and payer strategy for neffy, the Company’s needle-free epinephrine nasal spray. The complaint identifies him as a speaker on both the March 9, 2026 and May 15, 2026 earnings calls, where commercial coverage progress was the central investor topic.<\/p>\n

\n What Karas Allegedly<\/span> Told the Market<\/b>\n <\/p>\n

On March 9, 2026, Karas told investors the Company was “highly focused on CVS Caremark, Anthem and the large regional payers to ensure commercial coverage without restrictions,” citing approximately 93% overall commercial coverage with roughly 57% of covered lives accessing neffy without prior authorization, and approval rates near 55% where prior authorization applied. On May 15, 2026, as named in the action, he stated the CVS Caremark proposal was “in the final stages of the approval process” and that the payer process was “nearing completion.”<\/p>\n

\n Karas’s Alleged<\/span> Role<\/b>\n <\/p>\n